Brian Richardson

Nov 7, 2024 | drbrianrichardson.com | Brian Richardson

Urological surgery, which focuses on the diagnosis and treatment of urinary tract disorders and male reproductive health conditions, has seen tremendous advancements in recent years. These innovations have transformed patient outcomes, offering less invasive treatments, faster recovery times, and improved precision. As technology continues to evolve, several breakthroughs are reshaping the field of urology.

Sep 27, 2024 | urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson

September 27, 2024By The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods. Video content above is prompted by the following question:What are some unmet needs in prostate cancer care today, particularly regarding diagnosis, risk stratification and treatment? How can these gaps be addressed to improve patient outcomes? Related Content Related Content

Aug 23, 2024 | urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson

August 23, 2024By Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis. Video content above is prompted by the following question:How do you approach risk stratification in prostate cancer patients, specifically in those newly diagnosed? (Brian Richardson, MD)Do you rely on the Gleason score, specific biomarkers, or a combination? Related Content Related Content

Aug 23, 2024 | urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson

August 23, 2024By The key opinion leaders explore risk factors for prostate cancer, detailing both general risk groups and high-risk populations more susceptible to developing the disease. Video content above is prompted by the following question:We know that some patient populations are at a higher risk for developing prostate cancer. Please briefly discuss the general risk groups in prostate cancer. Related Content Related Content

Aug 16, 2024 | urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson

August 16, 2024By Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test. Video content above is prompted by the following question:In your clinical practice, are there specific situations in which you would choose serum, urine and/or tissue biomarkers? If so, can you expand on when you might use them? Related Content Related Content